B cells infected by Epstein-Barr virus (EBV), a transforming virus endemic in humans, are rapidly cleared by the immune system, but some cells harboring the virus persist for life. Under conditions of immunosuppression, EBV can spread from these cells and cause life-threatening pathologies. We have generated mice expressing the transforming EBV latent membrane protein 1 (LMP1), mimicking a constitutively active CD40 coreceptor, specifically in B cells. Like human EBV-infected cells, LMP1 + B cells were efficiently eliminated by T cells, and breaking immune surveillance resulted in rapid, fatal lymphoproliferation and lymphomagenesis. The lymphoma cells expressed ligands for a natural killer (NK) cell receptor, NKG2D, and could be targeted by an NKG2D-Fc fusion protein.
INTRODUCTION
EBV is a g-herpes virus infecting and potentially transforming human B-lymphocytes and establishing a life-long latent infection in more than 90% of human beings. Because EBV-infected B cells are rapidly eliminated by the immune system, EBV infection in childhood causes no or only mild symptoms, and primary infection occurring in young adults can lead to a self-limiting lymphoproliferative disorder known as infectious mononucleosis (Kutok and Wang, 2006) . T cells play a main role in this immune surveillance mechanism, but NK cells also participate (Hislop et al., 2007; Orange, 2006) . In infected individuals, EBV acquires a ''dormant'' state in a minute fraction of B cells and persists for life. Under conditions of immunosuppression, the virus can spread from these few cells, resulting in explosive expansion of infected B cells and their malignant transformation, as seen in pathologies such as posttransplant lymphoproliferative disorder (PTLD) and AIDS-associated B cell lymphoma (Kutok and Wang, 2006) . EBV is also associated with other B cell lymphomas, including Hodgkin's disease (HD) and Burkitt lymphoma (BL) (Kutok and Wang, 2006) , although the strategies used by the transformed cells in these diseases to evade immune surveillance are still elusive. A likely clue to this problem lies in the various states of latency, which EBV can assume, ranging from a highly restricted pattern of viral gene expression in BL (latency I) to the expression of just a few EBV genes in HD (latency II) and that of all latent genes in PTLD and AIDSassociated B cell lymphoma (latency III) (Capello et al., 2003; Kü ppers, 2003) .
The EBV-encoded proteins LMP1 and LMP2A share functions with receptors on normal B cells. LMP2A mimics a constitutively active B cell receptor (BCR), which it can replace in B cell development (Caldwell et al., 1998; Casola et al., 2004) . LMP1 is a functional homolog of constitutively active CD40, the major costimulatory receptor on B cells (Thorley-Lawson, 2001 ). LMP1 signals through tumor necrosis factor receptor (TNFR)-associated factors (TRAFs) or TNFR-associated death domain proteins (TRADD) to activate c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), p38, and canonical and noncanonical nuclear factor-kB (NF-kB), promoting cell growth and survival (Soni et al., 2007) .
LMP1 expression is essential for the transformation of human B cells by EBV (Kaye et al., 1993) and can by itself induce oncogenic transformation of rodent fibroblasts (Wang et al., 1985) . It has been reported that LMP1-positive B cell lymphomas sporadically develop in aged LMP1 transgenic mice. In these animals, LMP1 expression was barely detectable at young age, a phenomenon that is not yet understood (Kulwichit et al., 1998) .
Here, we describe a mouse model of conditional LMP1 expression that can be used to study EBV-induced immune surveillance and lymphomagenesis. This system also allowed us to validate a new therapeutic approach, potentially targeting EBV-driven malignancies in immunosuppressed patients.
RESULTS

LMP1 Promotes B Cell Growth In Vitro
To model EBV-associated B cell transformation, we generated a Rosa26 allele allowing expression of LMP1 through excision of a transcriptional/translational STOP cassette via Cre/loxPmediated recombination (LMP1 flSTOP ; Figure 1A ). B cells isolated from LMP1 flSTOP mice expressed LMP1 following treatment with TAT-Cre (Peitz et al., 2002 ) ( Figure 1B ) and proliferated in cell culture, whereas TAT-Cre-treated wild-type (WT) B cells died over time ( Figure 1C ). The induction of LMP1 was accompanied by an increase in cell size and the upregulation of CD95/Fas, as expected from earlier work (Le Clorennec et al., 2006; Uchida et al., 1999 ) ( Figure 1D ). We subsequently used Fas as a reporter for LMP1 expression in B cells.
Elimination of LMP1 + B Cells and Activation of T Cells
In Vivo LMP1 flSTOP mice were crossed to CD19-cre mice to induce LMP1 expression in B cells from the pro/pre-B cell stage (Rickert et al., 1995) . Unexpectedly, the B cell compartment in the spleen of adult CD19-cre;LMP1 flSTOP mice was significantly reduced compared to CD19-cre controls (Figure 2A and Figure S1A available online). The remaining B cells in the mutant mice had escaped deletion of the STOP cassette ( Figure S1B ). No Fasexpressing B cells were detected in the spleen (data not shown), although a small fraction of CD19 + Fas + B cells (LMP1 + B cells)
were seen in the bone marrow (BM; Figure 2B ). B cell development in the BM of the mutant mice was disrupted, with an increase of pro-B and decrease of pre-B immature and mature B cells (Figures S1C-S1E). Because LMP1 + B cells survived and proliferated in cell culture ( Figure 1C ), their counterselection in vivo is unlikely a consequence of LMP1 toxicity. Considering that EBV-infected human B cells are cleared by the host immune system, we sought for a similar immune surveillance mechanism in the mutant mice. Indeed, we detected increased populations of activated CD4 + and CD8 + T cells in the BM of the mutants ( Figures 2C, 2D , and S1F). In addition, on day 8 after birth, we found a significant population of CD19 + Fas + B cells in their spleen ( Figure 2E ). The dynamics of CD19 + Fas + B cells and activated CD4 + and CD8 + T cells in the mutant mice between day 3 and 8 after birth suggest that a T cell immune response is induced within this time period (Figures S2A-S2C ).
Disruption of Immune Surveillance Leads to Rapid, Fatal Expansion of LMP1 + B Cell Blasts in the Mutant Mice
To assess whether activated T cells are responsible for the elimination of LMP1 + B cells, we injected a cocktail of depleting antibodies (Abs) containing anti-CD4, -CD8, and -Thy1 into adult CD19-cre;LMP1 flSTOP and CD19-cre control animals at 3-4 day intervals. At 2 weeks after the initiation of this treatment, the majority of the mutant mice, but not the controls, became terminally ill, presenting with splenomegaly due to marked expansion of LMP1 + B cells (CD19 + Fas + ; Figures 3A and 3B ). These cells were largely confined to peripheral lymphoid organs and the BM ( Figure S3A ), although infiltrations into the liver and rarely into lung and kidney were occasionally seen (data not shown). No outgrowth of LMP1 + B cells was seen in mutant mice treated with anti-CD4, -CD8, or -Thy1 alone or a combination of anti-CD4 and -CD8 ( Figure S3A and data not shown). The latter depleted TCRab T cells as efficiently as the combination of anti-CD4, -CD8, and -Thy1 (data not shown), but the anti-Thy1 antibody might deplete TCRgd T cells, activated NK, and natural killer T (NKT) cells in addition. Outgrowth of LMP1 + B cells was also not seen upon treatment of the animals with anti-TNF-a and/or anti-IFN-g blocking antibodies (data not shown; see Extended Experimental Procedures for experimental details), although both of these cytokines have been implicated in antitumor immunity (Balkwill, 2009; Blankenstein and Qin, 2003;  Ikeda et al., 2002; Koebel et al., 2007) . The activated T cells in the bone marrow of CD19-cre;LMP1 flSTOP mice contained normal proportions of cells expressing IFN-g, TNF-a, IL-4, and IL-17, except for a 2-fold increase of the former in the CD8 + compartment ( Figure S3B) Figure 3C and data not shown). They had deleted the STOP cassette and expressed LMP1 ( Figure 3D and data not shown) as well as high levels of activation-induced cytidine deaminase (AID) transcripts and protein ( Figures 3E and 3F ), likely due to LMP1 signaling (He et al., 2003) . Compared to WT B cells and consistent with the signaling properties of LMP1 (Soni et al., 2007) , the LMP1 + B cells exhibited higher levels of p52 and lower levels of IkBa, indicating activation of the alternative and canonical NF-kB pathways. They also displayed higher levels of phospho-ERK and phospho-JNK (p46), but not phospho-p38 ( Figure S3C ). Approximately 5% of the cells were in the S or G2 phase of the cell cycle, in contrast to < 1% of control B cells ( Figure S3D ). Figure S1 and Figure S2 .
whereas some such cells were present on the TCRb À/À ;TCRd +/-and substantial numbers on the TCRb ;TCRd À/À background died over a period of 6-12 weeks. TCRgd T cells provided some protection, and in the presence of TCRab T cells, the animals readily survived the 24 week period of observation ( Figure 4D ).
LMP1 + Tumors Arise in T Cell-Ablated Mice
When terminally ill T cell-deficient CD19-cre;LMP1 flSTOP mice ( Figure 4D ) were examined for the cause of death, they all presented with splenomegaly and, occasionally, hepatomegaly. Most of these mice developed tumors histologically resembling diffuse large B cell lymphomas (DLBCL; six of nine cases), whereas plasmacytic tumors were seen in the others (three of nine cases) ( Figure 5A ). Immunohistochemically, all tumors analyzed were positive for interferon regulatory factor 4 (IRF4; five of five cases; Figure 5B and Table S1 ), a target of the NF-kB pathway (Saito et al., 2007) . Indeed, NF-kB activity in tumor cells was comparable to the signals detected in control B cells upon overnight CD40 stimulation, activating predominantly the alternative pathway ( Figure S4A ). Analysis of immunoglobulin heavy-chain (IgH) gene rearrangements by Southern blotting indicated that mice dying before 8 weeks of age displayed polyclonal B cell expansion, whereas older animals usually developed clonal B cell lymphomas, which could be propagated in immunodeficient (Rag2
), but not WT ((C57BL/6xBALB/c) F1), animals ( Figure 5C , Figure S4B , and data not shown). The tumor cells (CD19 + Fas + ) were AA4.1
À , CD21 + , and CD23 + and thus resembled mature follicular B cells ( Figure 5D , Table S1 , and data not shown). Of the four tumors analyzed for surface immunoglobulins (Igs), one was IgM + l + , one was IgM + k + , and the other two were IgG2 Figure 5E ). Class switch recombination (CSR) in the latter tumors may have been due to LMP1-induced AID expression (He et al., 2003; Rastelli et al., 2008) , which was indeed detectable in all LMP1 + lymphomas analyzed ( Figure S4C ). The rearranged V region genes of these tumors, however, were not modified by somatic hypermutation (SHM; data not shown). The superior efficiency of CD4 + T cells in tumor elimination was unexpected. Their antitumor activity was not mediated by IFNg and/or TNFa production, as it was completely preserved in the presence of antibodies blocking these cytokines (see Extended Experimental Procedures). There was also only a minor increase of T cells secreting these cytokines upon coculture with tumor cells ( Figure S5B ). NKT cells, representing 10%-20% of the CD4 + T cells in the bone marrow preparations, could not account for the antitumor activity of the CD4 + T cells because elimination of these cells by FACS on the basis of CD1d-tetramer staining had no effect ( Figure 6D ). We also tested NKT cells purified from the bone marrow of CD19-cre;LMP1 flSTOP mice for antitumor activity in the cell transfer system. Although limited by cell numbers, we were able to See also Figure S4 and Table S1 . express high levels of MHC I and II in conjunction with the costimulatory and adhesion molecules CD80, CD86, and CD54 (ICAM-1). To address this issue, we performed coculture experiments with activated B cells infected with an LMP1-encoding retrovirus and lacking either MHC II or MHC I antigen expression. Whereas both types of T cells proliferated in the presence of LMP1-expressing (but not mock-infected) activated wild-type B cells, the CD4 + T cells failed to respond to CIITA-deficient B cells that lack MHC II antigen expression, and the CD8 + T cells showed severely impaired response to b2 microglobulin (b2M) and thus MHC I-deficient B cells ( Figure 6F ). These results suggest that both types of T cells recognize the LMP1-expressing B cell blasts and, by extension, the LMP1-driven lymphoma cells by their TCR, through MHC-bound antigenic peptides. We attempted to pinpoint LMP1-derived peptides involved in this process by screening overlapping 20mers from every tenth amino acid position of LMP1 in a CD4 + T cell proliferation assay using activated B cell for presentation, but these attempts were unsuccessful (see Extended Experimental Procedures).
Immune Surveillance of LMP1-Driven Lymphomas
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Exploiting NKG2D for Immunotherapy
Extrapolating from the human (Hislop et al., 2007; Orange, 2006) , we speculated that the tumor cells may also be recognized by NK cells (Vivier et al., 2008) . Indeed, we found that, in spleen and BM of CD19-cre;LMP1 flSTOP mice, a fraction of the NK cells were activated, and this activation encompassed the entire NK cell population on a T cell-deficient background, where LMP1 + B cells gradually expand ( Figure 7A ). In addition, the stress antigen Rae-1, a ligand of a major NK-activating receptor termed NKG2D (Diefenbach et al., 2001) , was highly expressed on the surface of the LMP1 + lymphoma cells ( Figure 7B ). This could be due to AID expression as in Abelson murine leukemia virus-infected B cells, allowing their recognition by NK cells (Gourzi et al., 2006) . Accordingly, NK cells from CD19-cre;LMP1 flSTOP mice were able to kill LMP1 + lymphoma cells in vitro, and killing could be partially inhibited by an NKG2D-blocking antibody (Figure 7C) . Recognition of CD95/Fas, abundantly expressed on the tumor cells, also seemed to play a role in the killing reaction, as killing was also partially inhibited by a Fas-Fc fusion protein.
Addition of both antibodies had an additive effect. Although NK cells can thus recognize and attack LMP1 + B lymphoma cells, they seem to play only a minor role in the in vivo surveillance of these tumors, given that T cell-deficient CD19-cre;LMP1 flSTOP mice rapidly succumb to LMP1-driven lymphomas. Further supporting and extending this notion is our finding that CD19-cre;LMP1 flSTOP mice on a NKG2D-deficient background are perfectly protected against LMP1-driven lymphomagenesis ( Figure S6A ). Thus, NKG2D receptors, which are expressed not only on NK, but also several classes of activated T cells (Raulet, 2003) , are not critical for tumor surveillance in this system. Accordingly, like EBV-driven PTLD in the human (see below), the LMP1 + lymphomas in the present mouse model are not selected against NKG2D ligand expression, making them ideal targets for NKG2D-based therapy. Following this reasoning, we assessed whether these tumors can be targeted by an NKG2D-Fc fusion protein, constructed by fusing the NKG2D extracellular domain to an Fc fragment of mouse IgG2a, which can activate killing by complement-and cell-mediated cytotoxicity. Previous work showed that antibodies to MHC class I chain-related protein A (MICA), a human NKG2D ligand, stimulated killing of MICA-expressing tumor cells through complement-and cell-dependent cytotoxicity (Jinushi et al., 2006 (Jinushi et al., , 2008 . Thus, a murine NKG2D-Fc fusion protein might couple broad recognition of NKG2D ligand-expressing tumor cells to Fc-mediated killing mechanisms. As shown by flow cytometry, this protein readily bound to LMP1 + tumor cells (Figure 7D) , and the cells were efficiently lysed upon incubation with NKG2D-Fc and complement ( Figure 7E ). When tumor cells were transferred into immunodeficient recipient mice, treatment of the latter with moderate doses of NKG2D-Fc significantly reduced tumor growth and prolonged the survival of the animals ( Figures 7F, 7G , and S6B-S6E). Although the NKG2D-Fc-treated recipients eventually succumbed to tumor outgrowth, the tumor cells continued to express Rae-1 at the same (high) levels as those in animals treated with control antibody (data not shown). Optimizing the dose of NKG2D-Fc and combining it with cytokines such as granulocyte macrophage colony-stimulating factor to promote antibody-dependent cell-mediated cytotoxicity (Yu et al., 2010) will therefore be important considerations in attempts to apply this therapeutic approach in the clinic. Supporting the therapeutic potential of NKG2D-Fc fusion proteins in human EBV-driven pathologies, we found that six of six human EBV + PTLDs examined expressed high levels of NKG2D ligands ( Figure 7H ).
DISCUSSION
We demonstrate that expression of a single EBV protein, LMP1, in B cells is sufficient to induce immune surveillance of the LMP1 + cells by cells of the adaptive immune system and that weakening of this surveillance mechanism results in the rapid generation of LMP1-driven B cell lymphomas. Thus, this mouse model recapitulates two salient features of EBV infection in humans and offers itself for preclinical studies relating to the pathogenesis and therapy of EBV-driven malignancies under conditions of immunosuppression. In addition, the efficient immune surveillance of LMP1-expressing B cells likely explains the limited success of a previous attempt to induce B cell lymphomas through an LMP1 transgene (Kulwichit et al., 1998) . EBV-driven lymphomas in immunosuppressed patients seem typically to arise from post-GC B cells expressing somatically mutated antibodies (Vakiani et al., 2008) , as most of the virus in latently infected individuals seems to reside in such cells (Souza et al., 2005) . In contrast, the present mouse model is based on the transformation of newly generated B cells in a setting in which, due to constitutive T cell deficiency, GC B cells are not generated. Still, the tumors arising in the T cell-deficient LMP1 transgenic mice are remarkably similar to EBV-driven lymphomas in immunosuppressed patients. They are derived from phenotypically mature B cells (CD19 + , AA4.1
+ , CD23 + , and surface Ig + ) and, in most cases, morphologically resemble human DLBCL, as is typical for monomorphic PTLD (Harris et al., 2001) . As do the latter tumors (Craig et al., 2007; Vakiani et al., 2008) and consistent with active LMP1 signaling, they express the NF-kB target IRF4 (Saito et al., 2007) and AID (He et al., 2003) , the enzyme controlling CSR and SHM in normal B cell development. The expression of CSRdependent antibody isotypes by some of the tumors is another feature shared by lymphomas arising in immunosuppressed patients (Vakiani et al., 2008) . Thus, although PTLD and AIDSassociated B cell lymphoma express multiple EBV latency genes, our results underscore a central pathogenic role for LMP1 alone. A striking result of the present work is the efficiency and tempo of LMP1-induced B cell lymphomagenesis in the LMP1 transgenic, T cell-deficient animals. At 3 months after birth, essentially all such animals have died from aggressive, monoclonal B cell tumors. This not only highlights the potential of LMP1 to transform B cells in vivo, but also suggests that LMP1 expression induces in the cells secondary oncogenic events, resulting in the rapid outgrowth of monoclonal lymphomas. A candidate pathway in this respect is the LMP1-induced expression of AID (He et al., 2003) , given the known oncogenic properties of AID in terms of mediating chromosomal translocations and introducing point mutations into non-Ig loci (Pasqualucci et al., 2001; Ramiro et al., 2004) . A search for secondary oncogenic events in the LMP1-induced tumors is ongoing and should be directly relevant for the pathogenesis of EBV-driven lymphomas in immunosuppressed patients.
The efficient immune surveillance of LMP1-expressing B cells and of the resulting lymphomas resembles that of EBV-infected B cells in the human and points to a major role of LMP1 in the latter context. In both settings, TCRab cells are clearly the major players, with the present data indicating no more than an ancillary role for TCRgd cells. However, overall, our data do suggest some participation of TCRgd cells, NKT, and activated NK cells in the surveillance of the LMP1 + cells, a notion also supported by the need for anti-Thy1 in addition to anti-CD4 and -CD8 antibodies in the breaking of immune surveillance.
In vivo, activated CD4 + and CD8 + T cells appeared at the site of generation of LMP1 + B cells, namely in the BM, and at least some of these cells were able to specifically recognize the LMP1 + B cells, as demonstrated by in vitro killing and in vivo protection assays. For both classes of T cells, recognition of the LMP1 + B cell blasts was MHC restricted and thus indicative of TCR-based recognition of peptide-MHC complexes. The nature of the peptides involved in this process is presently a matter of speculation. Though our failure to pinpoint LMP1-derived T cell epitopes does not exclude their existence, it is in line with the absence of detectable immune surveillance of mouse B cells expressing reciprocal LMP1-CD40 fusion proteins Rastelli et al., 2008) . The recognition of the LMP1 + B cells could involve a wide range of tumor-specific and self-antigens that have been identified as T cell targets on tumor cells (Boon et al., 2006) . In human EBV-infected B cells, these would include peptides from a variety of EBV proteins, prominently the EBV nuclear antigens, with LMP1 peptides playing a minor role, if any (Hislop et al., 2007) . Though the recognition of EBV-infected and transformed B cells likely involves a multitude of peptide-MHC complexes, the present results indicate that LMP1 plays a crucial role in the induction of immune surveillance. We suggest that this is due to the strong and chronic activation of B cells by LMP1 through signaling pathways resembling those initiated by CD40 ligation. Like CD40-activated B cells, B cells expressing LMP1 display high levels of costimulatory and adhesion molecules on their surface, which have been shown to critically enhance the immunogenicity of human B cell lymphomas through effective presentation of tumor alloantigens to T cells (Schultze et al., 1995 (Schultze et al., , 1997 .
Surprisingly, in the in vivo tumor protection assays CD4 + cells were superior to CD8 + cytotoxic cells despite their inability to kill the tumor cells in vitro and functional independence of IFNg or TNFa production. CD4 + T cells have been shown in another context to exhibit antitumor activity in vivo by developing into cytotoxic effectors (Quezada et al., 2010) . Current immunotherapy of EBV-driven diseases in transplant recipients includes infusion of EBV-specific cytotoxic T lymphocytes (CTLs) generated from autologous or donor-derived peripheral-blood mononuclear cells (Gottschalk et al., 2005; Savoldo et al., 2006) . In most cases, these are predominantly CD8 + T cells, but sometimes CD4 + T cells predominate and seem to display similar therapeutic efficacy. The present results draw attention to the potential therapeutic value of EBV-specific CD4 + T cells in the treatment of EBV-associated malignancies in the human.
A new aspect of the surveillance of LMP1 transformed B cells emerging from the present work comes from the expression of stress antigens on these cells, likely due to LMP1-induced AID activity (Gourzi et al., 2006) . These stress antigens, which we found also highly expressed on human PTLDs, are recognized by activating NK cell receptors, which are also expressed on activated CD8
+ and NKT cells (Raulet, 2003) . Though NK cells by themselves were unable to prevent LMP1-driven lymphomagenesis, we have developed a therapeutic approach for the treatment of these tumors using the antigen binding domain of the activating NK receptor NKG2D as a soluble protein, fused to the Fc region of an antibody. We show in a proof-of-principle experiment that injection of this fusion protein into recipients of lymphoma cells strongly impedes the outgrowth of these highly aggressive tumors in our preclinical mouse model. Future studies will examine the relative contributions of complementdependent and phagocyte-mediated killing to the antitumor effects. Because NKG2D ligands show limited expression in healthy tissues, the NKG2D-Fc fusion protein might achieve a favorable therapeutic index in PTLD patients. Indeed, high titers of anti-MICA antibodies are associated with clinically meaningful responses to cancer immunotherapy in the absence of toxicity (Jinushi et al., 2006) . Though our preclinical evaluation of the NKG2D-Fc fusion protein focused on early tumors, reflecting the rapid growth kinetics of the transplantable lines, future clinical investigations should explore the optimal timing of NKG2D-Fc administration and a potential integration with other forms of lymphoma therapy. Finally, as NKG2D ligands are expressed by diverse hematologic and solid malignancies, the NKG2D-Fc fusion protein might also prove applicable to other clinical settings. Efforts to translate this therapeutic strategy to testing in patients are underway.
EXPERIMENTAL PROCEDURES Mice and Depleting Antibody Treatment
To generate conditional LMP1 transgenic mice, the LMP1 coding sequence derived from the EBV B95-8 strain, preceded by a loxP-flanked Neo r -STOP cassette, was cloned into the ubiquitously expressed Rosa26 locus (Sasaki et al., 2006 The cells were stained with anti-TCRb, -CD4, -CD8, and -CD19 and analyzed for CFSE levels.
NKG2D-Fc Fusion Proteins
Expression vectors were prepared with In-Fusion (Clontech) assembly, using previously reported procedures and modular cassettes (Zhu et al., 2007) . Because NKG2D is a type II transmembrane protein, the DNA constructs were composed of an optimized IL-2 signal sequence (Zhang et al., 2005) , the hinge-CH2-CH3 domains of mouse IgG2a beginning with EPKGP, an IEGR linker, and the extracellular domain of either murine (amino acids 94-232; #AF054819) or human (amino acids 78-216) NKG2D (designated mNKG2D-Fc and hNKG2D-Fc, respectively). Plasmids were electroporated into Chinese hamster ovary DG44 cells, and stable clones were generated with methotrexate selection. High producers were identified through assaying culture supernatants for mIgG2a with an ELISA. Large-scale preparation of the mNKG2D-Fc protein was performed commercially (Bio X Cell). The hNKG2D-Fc protein was purified from conditioned supernatants with recombinant protein G agarose (Invitrogen), according to the manufacturer's protocols. For FACS analysis, cells were stained with 10 mg/ml of mNKG2D-Fc or control mIgG2a followed with a PE-conjugated goat anti-mouse IgG (Southern Biotechnology). For complement-dependent lysis, tumor or control B cells were suspended in cytotoxicity medium (RPMI plus 0.3% BSA) at 4 3 10 6 cells/ml and then incubated for 2 hr at 37 C in varying concentrations of mNKG2D-Fc or control mIgG2a and rabbit complement (Cedarlane Laboratories) diluted with 7-AAD (BD Biosciences 
